

Theme: Personalized therapy for optimal care

PROGRAM DAY 1 – 4th May, Saturday

(Preliminary & Subject to change)

Session I: General Session

Chairs : Toh Han Chong, TBA

8.20-8.30AM : Opening Remarks: Toh Han Chong, Singapore

8.30 – 9.00AM : Key note lecture

The evolving role personalized GI cancer care: The past, the present, the future

Axel Grothey, USA

9.00 – 9.30AM : An ariel view of 2018: What did we learn ?

Shaheenah Dawood, UAE

9.30 - 10.00AM

Multidisciplinary tumor board 1 : Molecular tumor board for GI Cancers

Axel Grothey, US | Panel : TBA

10.00 – 10.30 Coffee Break

Organised by

Session II : Immunotherapy in GI cancers (10.30 – 12.00)

Chairs: TBA

10.30 -10.40

Five important questions we want to answer today!

Toh Han Chong, Singapore

10.40– 11.00 : Immunotherapeutics in HCC

TBA

11.00-11.20

Immunotherapeutics in Gastric cancer (A scientific update of immunotherapy in Gastric Cancer)

TBA

11.20-11.40 : Immunotherapeutics in Colorectal Cancer

Shaheenah Dawood, UAE

11.40-12.10 pm

Multidisciplinary tumor board 2: Using checkpoint inhibitors: Real world cases

Sun Young Rha, South Korea | Panel TBA

Panel: TBA

12.10 – 13.00

Lunch Break: BAYER SATELLITE SYMPOSIUM

Organised by



INDEX® Conferences & Exhibitions Organisation Est.

P.O. Box: 13636 | Dubai-UAE | INDEX Holding Headquarters | Road #D-62 | Opp. Nad Al Hamar

Tel: +971 4 520 8888 | Fax: +971 4 338 4193 | E-mail: info@apgcs.com | index.ae

www.apgcs.com

Session III: Personalizing therapy for HCC

Chairs : Pierce Chow, TBA

1.00– 1.20PM

Portending the future: How will a positive 1st line trial with check-point inhibitors in HCC change the treatment paradigm in HCC

Thomas Yau, HK

1.20 -1.40PM

Portending the future: If there were a negative 1st line trial with check-point inhibitors in HCC, what would subsequent clinical trials be like?

Stephen Chan, HK

1.40-2.00PM

Emerging Paradigms in the management of locally advanced HCC

Bruno Sangro, Spain

2.00 – 2.20pm

The potential for cure with resection in HCC – a metro-ticket approach

Pierce Chow, Singapore

2.20 – 2.30PM

Q&A

2.30 – 3.00pm

Multidisciplinary tumor board 3 : Real World Management of HCC

Panel TBA

Organised by

3.00 – 3.30 Coffee with Satellite Symposium – MSD

Advances in the management of Advanced/ Metastatic esophageal cancer with Immunotherapy

Sung Bae Kim, South Korea

Session IV: Controversies in the management of gastric /pancreatic cancer

Chairs : Shailesh Shrikande, India, TBA

3.30 – 3.30PM

Personalized therapy for advanced gastric cancer: are we there yet?

TBA

3.30 -4.00PM

Debate 1: All patients with resectable pancreatic cancer should receive neoadjuvant chemotherapy first

Yes : Medical oncologist TBA

No : Shailesh Shrikande, India

4.00-4.30PM

The evolving role of personalized therapy in advanced pancreatic cancer

TBA

Organised by

PROGRAM DAY 2 – 5th May, Sunday

8.30 – 9.00AM: Keynote Lecture: Sabine Tejpar, Belgium

The molecular and immune biology of Colorectal cancer as it relates to clinical treatments: a summary what we have learnt in the last 2 years –

Pragmatic / contemporary issues in Colorectal Cancer: How does existing & recent data influence clinical decision making in the following situations?

Session V: Challenging clinical scenarios

Case Discussion Facilitator: local faculty TBA

Panelists : Sabine Tejpar, Axel Grothey, Takayuki Yoshino, Ian Chau

9.00 – 9.40AM

What is the ideal adjuvant chemotherapy in different clinical scenarios / patient profiles (colon cancer)

Axel Grothey, USA

Case Discussion : Facilitated by Chee Cheng Ean, Singapore

Additional local faculty: Clarinda Chua, Singapore

9.40 – 10.20AM

Right-sided Colon cancer: What is the optimal treatment sequence in right sided colon cancer for (a) conversion therapy (b) high volume disease (c) intermediate volume disease

Takayuki Yoshino, Japan

Session is supported by Merck Serono

Case Discussion: Facilitated by Iain Tan, Singapore

Additional local faculty: Wei Peng

Organised by

10.20 – 10.40 Coffee Break

10.40 – 11.20AM

MSI-H CRC – It's impact on adjuvant treatment decisions, and in late stage, sequencing of immunotherapy and chemotherapy and management at progression – current data –

Koo Si Lin, Singapore

Session is supported by BMS

Case Discussion: Facilitated by Raghav Sundar, Singapore

Additional local faculty: Koo Si Lin

11.20 – 12.00PM

Management of synchronous Rectal Cancer in the presence of resectable distant metastases

Chean Ean, Singapore

Case Discussion : Facilitated by Tan Wah Siew, Singapore

Additional local faculties: Tan Ker Kan, Connie Yip, Chan Chung Yip, Alfred Kow

12.00 – 12.40PM

Selecting antiangiogenic agents in 1st, maintenance and beyond progression: practical considerations

Ian Chau, UK

Session is Supported by Lilly Oncology

Case Discussion : Facilitated by Wei Peng

Additional local faculty : TBA

12.40 CLOSING REMARKS & LUNCH

Organised by